These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

650 related items for PubMed ID: 12690668

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. [L-DOPA-induced dyskinesia].
    Derkinderen P, Vidailhet M.
    Rev Neurol (Paris); 2002; 158(122):92-101. PubMed ID: 12690319
    [Abstract] [Full Text] [Related]

  • 3. [Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)].
    Damier P, Tremblay L, Féger J, Hirsch EC.
    Rev Neurol (Paris); 2000 Mar; 156(3):224-35. PubMed ID: 10740093
    [Abstract] [Full Text] [Related]

  • 4. [Social and economic cost of L-Dopa-induced dyskinesias in patients with Parkinson's disease].
    Maurel F, Lilliu H, Le Pen C.
    Rev Neurol (Paris); 2001 May; 157(5):507-14. PubMed ID: 11438770
    [Abstract] [Full Text] [Related]

  • 5. Dyskinesias predict the onset of motor response fluctuations in patients with Parkinson's disease on L-dopa monotherapy.
    Mazzella L, Yahr MD, Marinelli L, Huang N, Moshier E, Di Rocco A.
    Parkinsonism Relat Disord; 2005 May; 11(3):151-5. PubMed ID: 15823479
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Physiopathology of the dyskinesias induced by L-dopa].
    Grandas F, López-Ariztegui N.
    Rev Neurol; 1997 Aug; 25 Suppl 2():S151-6. PubMed ID: 9280682
    [Abstract] [Full Text] [Related]

  • 9. The spectrum of levodopa-induced dyskinesias.
    Fahn S.
    Ann Neurol; 2000 Apr; 47(4 Suppl 1):S2-9; discussion S9-11. PubMed ID: 10762127
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification.
    Luquin MR, Scipioni O, Vaamonde J, Gershanik O, Obeso JA.
    Mov Disord; 1992 Apr; 7(2):117-24. PubMed ID: 1350058
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
    Muñoz A, Li Q, Gardoni F, Marcello E, Qin C, Carlsson T, Kirik D, Di Luca M, Björklund A, Bezard E, Carta M.
    Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
    [Abstract] [Full Text] [Related]

  • 15. Rating scales for dyskinesias in Parkinson's disease.
    Goetz CG.
    Mov Disord; 1999 Dec; 14 Suppl 1():48-53. PubMed ID: 10493403
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Risk factors in development of motor complications in Chinese patients with idiopathic Parkinson's disease.
    Kum WF, Gao J, Durairajan SS, Man SC, Xie LX, Lu JH, Fong WL, Li M.
    J Clin Neurosci; 2009 Aug; 16(8):1034-7. PubMed ID: 19428256
    [Abstract] [Full Text] [Related]

  • 18. Disordered respiration as a levodopa-induced dyskinesia in Parkinson's disease.
    Rice JE, Antic R, Thompson PD.
    Mov Disord; 2002 May; 17(3):524-7. PubMed ID: 12112201
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.